|
|
 |
|
Viewing report
|
|
|
|
Do the Emerging Treatments for Celiac Disease Offer Significant Improvements over the Gluten-Free Diet?
Decision Resources, Inc, Sep 2011
Celiac disease is an autoimmune disorder caused by ingestion of gluten-containing foods in genetically susceptible people. These individuals develop extensive damage in their small intestine upon consuming gluten-containing foods. Only one therapy is available for these patients—a gluten-free diet. Interviewed experts watch with interest the clinical development of other therapies for celiac disease patients. This market presents a substantial opportunity for drug developers.
Questions answered in this report:
- A gluten-free diet is the only therapy available to celiac disease patients. What is the opinion of experts regarding the gluten-free diet? Are physicians satisfied with this therapy? What are the challenges of following a gluten-free diet? Does a gluten-free diet work for all celiac disease patients?
- A few agents are in development for treating celiac disease. How will these therapies be used to treat celiac disease patients? Do they offer any improvements over a gluten-free diet? What do thought-leading experts think of these agents?
- The percentage of diagnosed cases is surprisingly low for celiac disease. What is the average rate of diagnosis of celiac disease? What is the estimated prevalence of celiac disease in the U.S. population?
- Interviewed experts indicate that new therapies for celiac disease patients are a high unmet need. What other areas of unmet need do interviewed experts identify? In the opinion of the interviewed experts, how crucial are these unmet needs? Will any of the emerging agents address these unmet needs?
Scope:
Overview: Pathogenesis, predisposing genetic factors, symptoms and diagnosis of celiac disease.
Markets covered: United States.
Primary research: Five interviews with thought leaders who are pediatric or adult gastroenterologists in the United States and work closely with celiac disease patients.
Emerging therapies: Phase I: 1 drug; Phase II: 5 drugs.
Unmet needs: Considerations for drug developers.
|
|
|
|
